Takeda Pharmaceutical Company Limited Share Price
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,540.00 JPY | +2.12% |
|
+0.49% | +14.58% |
| 08-06 | Takeda Wins FDA Approval for First-in-Class Narcolepsy Treatment ORZEYFUL | MT |
| 08-06 | Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1 | CI |
| Market Cap | 8,662B 54.68B 47.45B 44.43B 40.65B 76.73B 5,209B 77.74B 520B 204B 2,603B 205B 201B | P/E 2027 * |
43.6x | P/E 2028 * | 27x |
|---|---|---|---|---|---|
| Enterprise Value | 12,589B 79.47B 68.96B 64.57B 59.07B 112B 7,570B 113B 755B 296B 3,782B 298B 292B | EV / Sales 2027 * |
2.7x | EV / Sales 2028 * | 2.62x |
| Free-Float |
99.28% | Yield 2027 * |
3.77% | Yield 2028 * | 3.84% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +2.12% | ||
| 1 week | +0.49% | ||
| Current month | +0.49% | ||
| 1 month | +1.69% | ||
| 3 months | +4.33% | ||
| 6 months | +0.65% | ||
| Current year | +14.58% |
| 1 week | 5,225 |  | 5,541 |
| 1 month | 5,225 | | 5,903 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 23/06/2026 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 31/03/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 31/05/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 31/12/2018 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 31/05/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/07/26 | Issuer sale | Director | -1,152 | 0.0001% | ||
| 10/07/26 | Issuer sale | President, Japan Pharma B.U. | -1,022 | 0.0001% | ||
| 10/07/26 | Issuer sale | Director | -1,152 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.12% | +0.49% | +30.97% | +26.69% | 54.68B | |
| +1.89% | +3.20% | +59.70% | +165.18% | 1,062B | |
| -0.24% | +0.45% | +50.64% | +52.02% | 619B | |
| -0.95% | -5.26% | +24.23% | +65.08% | 431B | |
| +2.43% | +5.29% | +49.46% | +40.57% | 358B | |
| +0.96% | -0.39% | +35.52% | +40.35% | 293B | |
| +1.40% | -5.06% | +9.52% | +10.17% | 247B | |
| -0.73% | +4.44% | +42.22% | +66.41% | 219B | |
| +4.64% | +0.10% | -0.66% | -43.78% | 200B | |
| -0.68% | -0.32% | +18.66% | +66.32% | 162B | |
| Average | +0.79% | -2.22% | +32.03% | +48.90% | 364.7B | |
| Weighted average by Cap. | +0.22% | -0.89% | +41.00% | +77.49% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,668B 29.47B 25.57B 23.95B 21.91B 41.35B 2,807B 41.89B 280B 110B 1,403B 111B 108B | 4,747B 29.97B 26B 24.35B 22.27B 42.05B 2,855B 42.6B 285B 112B 1,426B 113B 110B |
| Net income | 191B 1.2B 1.04B 978M 894M 1.69B 115B 1.71B 11.44B 4.49B 57.27B 4.52B 4.42B | 316B 2B 1.73B 1.62B 1.48B 2.8B 190B 2.84B 18.98B 7.45B 95.03B 7.5B 7.33B |
| Net Debt | 3,926B 24.79B 21.51B 20.14B 18.42B 34.78B 2,361B 35.23B 236B 92.47B 1,180B 93.06B 91.04B | 3,764B 23.76B 20.62B 19.31B 17.66B 33.35B 2,264B 33.78B 226B 88.66B 1,131B 89.22B 87.28B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/08/26 | JP¥5,540.00 | +2.12% | 4,116,100 |
| 06/08/26 | JP¥5,425.00 | +2.96% | 4,077,000 |
| 05/08/26 | JP¥5,269.00 | -0.32% | 3,470,800 |
| 04/08/26 | JP¥5,286.00 | -2.26% | 3,851,800 |
| 03/08/26 | JP¥5,408.00 | -1.90% | 4,750,600 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
